Clinical trials: Sunitinib
Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
This phase I trial is studying the side effects and best dose of bevacizumab and sunitinib in treating patients with solid tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00357318
- Testing
- sunitinib malate, bevacizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
This is a post-marketing Surveillance study to observe INLYTA® treatment dosing pattern, safety and effectiveness in Taiwan real world routine practice.
- Trial name
- NCT02533258
- Volunteers
- 13 people
- Sponsor
- Pfizer
Recurrent Disease, Squamous Cell Head and Neck Carcinoma
Efficacy of SU 011248 in Head And Neck Carcinoma
Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST.
- Conditions
- Recurrent Disease, Squamous Cell Head and Neck Carcinoma, Palliative Treatment
- Trial name
- NCT00408252
- Testing
- biopsies, SU011248
- Where
- 9 sites in Belgium, France
- Volunteers
- 54 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01620216
- Testing
- Antitumor Drug Screening Assay, Dasatinib, Idelalisib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Esophageal Cancer
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.
- Trial name
- NCT00400114
- Testing
- Irinotecan, Cisplatin, Radiation
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00787787
- Testing
- sunitinib malate, capecitabine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Renal Cell Cancer
Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
While different lines of evidence support the notion that renal cell cancer is amenable for immunologic vaccination, up to now the clinical benefit associated with vaccines has been limited.
- Trial name
- rcc (NCT00890110)
- Testing
- Autologous renal cell vaccine based on DNP modified cells
- Volunteers
- 13 people
- Sponsor
- Hadassah Medical Organization
Renal Cell Cancer, Kidney Cancer
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
The goal of this clinical research study is to find the highest tolerable dose of the combination of sunitinib and temsirolimus that can be given to patients with metastatic kidney cancer.
- Trial name
- NCT01122615
- Testing
- Sunitinib, Temsirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
- Trial name
- NCT00451048
- Testing
- sunitinib malate
- Where
- 4 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Advanced Solid Tumors
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.
- Trial name
- ICK (NCT01636908)
- Testing
- Sunitinib, Sorafenib, Erlotinib
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Amsterdam UMC, location VUmc
Ovarian Cancer, Adverse Effects
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Patients with early and advanced stages of epithelial ovarian cancer are treated with postoperative systemic chemotherapy after appropriate surgical staging and cytoreductive surgery.
- Trial name
- NCT01824615
- Testing
- Sunitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Cathay General Hospital
Clear Cell Renal Cell Carcinoma
Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
This is a prospective single arm phase II study to evaluate potential prognostic and/or predictive biomarkers in patients with metastatic ccRCC undergoing treatment with 1st line sunitinib on a 4/2 schedule followed by axitinib…
- Trial name
- SuAx (NCT03592199)
- Testing
- Sunitinib
- Where
- Brazil
- Volunteers
- 7 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Carcinoma, Renal Cell
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI)…
- Trial name
- NCT06222593
- Testing
- Bicalutamide in combination with Sunitinib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- State University of New York at Buffalo
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to…
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02761057
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 595 sites in United States, Canada
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma AJCC v7
- Trial name
- NCT00381641
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Sunitinib
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
This study is designed to explore the molecular modulatory effect of Sunitinib when given in a neoadjuvant setting prior to radical or partial nephrectomy.
- Trial name
- NCT01070186
- Testing
- Sunitinib, Tumor biopsy, Nephrectomy
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma, Liver Cancer
SU011248 in Advanced Hepatocellular Carcinoma
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer.
- Trial name
- NCT00361309
- Testing
- SU011248
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery.
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- ASSURE (NCT00326898)
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 987 sites in United States, Canada and 1 more
- Volunteers
- 1,943 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin, Multiple Myeloma
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- CAPTUR (NCT03297606)
- Testing
- Olaparib, Dasatinib, Nivolumab plus Ipilimumab
- Where
- 10 sites in Canada
- Volunteers
- 720 people
- Sponsor
- Canadian Cancer Trials Group
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision